BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31195139)

  • 1. Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.
    Nishimoto M; Hirose A; Koh H; Nakamae M; Nanno S; Okamura H; Nakane T; Nakashima Y; Hino M; Nakamae H
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2061-2069. PubMed ID: 31195139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide.
    Kurita N; Sakamoto T; Kato T; Kusakabe M; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    Ann Hematol; 2021 May; 100(5):1295-1301. PubMed ID: 33580280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide.
    Mariotti J; Taurino D; Marino F; Bramanti S; Sarina B; Morabito L; De Philippis C; Di Vito C; Mavilio D; Carlo-Stella C; Della Porta M; Santoro A; Castagna L
    Cancer Med; 2020 Jan; 9(1):52-61. PubMed ID: 31702882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated.
    Abboud R; Keller J; Slade M; DiPersio JF; Westervelt P; Rettig MP; Meier S; Fehniger TA; Abboud CN; Uy GL; Vij R; Trinkaus KM; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1851-1860. PubMed ID: 27318038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High plasma IL-6 levels following haploidentical allogeneic hematopoietic stem cell transplantation post-transplant cyclophosphamide as predictor of early death and worse outcome.
    Farias MG; de Mello Vicente B; Habigzang M; Hirakata VN; de Oliveira da Silva P; Paz AA; Daudt LE
    Transpl Immunol; 2022 Apr; 71():101543. PubMed ID: 35093504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide.
    Solán L; Landete E; Bailén R; Dorado N; Oarbeascoa G; Anguita J; Díez-Martín JL; Kwon M
    Hematol Oncol; 2020 Oct; 38(4):597-603. PubMed ID: 32592410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
    Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor KIR2DS1-Mediated Decreased Relapse and Improved Survival Depending on Remission Status at HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.
    Ido K; Koh H; Hirose A; Okamura H; Koh S; Nanno S; Nishimoto M; Nakamae M; Nakashima Y; Nakane T; Hino M; Nakamae H
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):723-733. PubMed ID: 31899360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography.
    Marani C; Raiola AM; Morbelli S; Dominietto A; Ferrarazzo G; Avenoso D; Giannoni L; Varaldo R; Gualandi F; Grazia D; Lamparelli T; Bregante S; Van Lint MT; Ibatici A; Bovis F; Lemoli RM; Gobbi M; Bacigalupo A; Angelucci E
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2501-2508. PubMed ID: 30041010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine release syndrome after haploidentical hematopoietic stem cell transplantation with antithymocyte globulin: risk factors analysis and poor impact on outcomes for non-remisssion patients.
    Xu Z; Zhou X; Zhao X; Lu X; Tang L; Shi W; Yan H; You Y; Wang H
    Hematology; 2021 Dec; 26(1):809-817. PubMed ID: 34602023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
    Otoukesh S; Elmariah H; Yang D; Clark MC; Siraj M; Ali H; Mogili K; Arslan S; Nishihori T; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Al Malki MM; Bejanyan N
    Transplant Cell Ther; 2022 Feb; 28(2):111.e1-111.e8. PubMed ID: 34844022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.
    Raj RV; Hamadani M; Szabo A; Pasquini MC; Shah NN; Drobyski WR; Shaw BE; Saber W; Rizzo JD; Jerkins J; Fenske TS; D'Souza A; Dhakal B; Zhang C; Konings S; Hari PN; Chhabra S
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1664-1670. PubMed ID: 29680516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation.
    Imus PH; Blackford AL; Bettinotti M; Luznik L; Fuchs EJ; Huff CA; Gladstone DE; Ambinder RF; Borrello IM; Fuchs RJ; Swinnen LJ; Wagner-Johnston N; Gocke CB; Ali SA; Bolaños-Meade FJ; Jones RJ; Dezern AE
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2431-2437. PubMed ID: 31394272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Ureshino H; Ando T; Kizuka H; Kusaba K; Sano H; Nishioka A; Itamura H; Shindo T; Kubota Y; Kojima K; Kimura S
    Hematol Oncol; 2018 Feb; 36(1):324-327. PubMed ID: 28971493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
    Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
    J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors.
    Nakamae H; Fujii K; Nanno S; Okamura H; Nakane T; Koh H; Nakashima Y; Nakamae M; Hirose A; Teshima T; Hino M
    Transpl Int; 2019 Dec; 32(12):1322-1332. PubMed ID: 31432532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients.
    Bacigalupo A; Maria Raiola A; Dominietto A; Di Grazia C; Gualandi F; Lint MTV; Chiusolo P; Laurenti L; Sora F; Giammarco S; Angelucci E
    Bone Marrow Transplant; 2019 Aug; 54(Suppl 2):708-712. PubMed ID: 31431716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of Initiation of Calcineurin Inhibitors in Pediatric Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Effects on Survival, Relapse, and Cytokine Release Syndrome.
    Uygun V; Karasu G; Yalçın K; Öztürkmen S; Daloğlu H; Çelen SS; Hazar V; Yeşilipek A
    Acta Haematol; 2022; 145(4):362-370. PubMed ID: 34847551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.